SEC Form 4 · accession 0001209191-15-000187
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Perry A Karsen
Officer — see remarks
Period of report
Dec 30, 2014
Accepted (ET)
Jan 2, 2015 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 30, 2014 | M | 23,334 | $29.75 | A | 74,744 | D | |
| Common StockF1 | Dec 30, 2014 | S | 19,273 | $113.37 | D | 55,471 | D | |
| Common Stock | holding | — | — | — | 2,000 | I | IRA Account | |
| Common Stock | holding | — | — | — | 1,461 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $29.75 | Dec 30, 2014 | M | 23,334 | D | — | Dec 27, 2020 | Common Stock | 23,334 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $112.78 to $114.25, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The option was fully exercisable.
- F3The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).
Remarks
Chief Executive Officer, Celgene Cellular Therapeutics